FDA Approves Tyenne, an Actemra Biosimilar for Autoinflammatory Diseases
source: shutterstock.com

FDA Approves Tyenne, an Actemra Biosimilar for Autoinflammatory Diseases

In early March 2024, Tyler Patchen reported that the U.S. Food and Drug Administration (FDA) approved both intravenous and subcutaneous formulations of Tyenne (tocilizumab-aazg) for use in a variety of…

Continue Reading FDA Approves Tyenne, an Actemra Biosimilar for Autoinflammatory Diseases
Celiac Disease Could Increase Risk of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
source: pixabay.com

Celiac Disease Could Increase Risk of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis

Editor's Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable agencies that wish to speak…

Continue Reading Celiac Disease Could Increase Risk of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
Rare Community Profiles: Kenzi’s Commitment to Raising Familial Cold Autoinflammatory Syndrome (FCAS) Awareness
Photo courtesy of Kenzi Cabrera

Rare Community Profiles: Kenzi’s Commitment to Raising Familial Cold Autoinflammatory Syndrome (FCAS) Awareness

Rare Community Profiles     Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their…

Continue Reading Rare Community Profiles: Kenzi’s Commitment to Raising Familial Cold Autoinflammatory Syndrome (FCAS) Awareness
Patient Advocate Anna Ellis Discusses Rare Disease Awareness and Drug Development
source: shutterstock

Patient Advocate Anna Ellis Discusses Rare Disease Awareness and Drug Development

Contributed by Anna Ellis Every February 28, millions of people around the world participate in Rare Disease Day to raise awareness about the more than 10,000 identified rare diseases that affect…

Continue Reading Patient Advocate Anna Ellis Discusses Rare Disease Awareness and Drug Development
Adolescents with JIA Have Longer Rheumatology Wait Times
Source: https://pixabay.com/en/boy-man-sitting-thinking-waiting-1149957/

Adolescents with JIA Have Longer Rheumatology Wait Times

Adolescence is the phase which exists between childhood and adulthood; therefore, people who are between ages 10-19 are typically considered to be adolescents. How does adolescence change the way people…

Continue Reading Adolescents with JIA Have Longer Rheumatology Wait Times
Simponi Aria (Golimumab) Approved for Juvenile Arthritis Types pJIA and jPsA
https://pixabay.com/en/baby-child-cute-doll-expression-17366/

Simponi Aria (Golimumab) Approved for Juvenile Arthritis Types pJIA and jPsA

Recently, the Janssen Pharmaceutical Companies of Johnson & Johnson ("Janssen") announced the FDA approval of Simponi Aria (golimumab). The therapy is designed to treat pediatric patients (ages 2 or older)…

Continue Reading Simponi Aria (Golimumab) Approved for Juvenile Arthritis Types pJIA and jPsA
Juvenile Arthritis Awareness Month: Teen Living with Juvenile Idiopathic Arthritis Isn’t Slowing Down
source: pixabay.com

Juvenile Arthritis Awareness Month: Teen Living with Juvenile Idiopathic Arthritis Isn’t Slowing Down

According to a story from gopresstimes.com, Lily Laurent, a 13 year old student at De Pere middle school in Wisconsin, has lived with juvenile idiopathic arthritis for nine years. While…

Continue Reading Juvenile Arthritis Awareness Month: Teen Living with Juvenile Idiopathic Arthritis Isn’t Slowing Down
Early Treatment of Juvenile Idiopathic Arthritis Improves Outcomes, Inactivates Disorder
IAOM-US / Pixabay

Early Treatment of Juvenile Idiopathic Arthritis Improves Outcomes, Inactivates Disorder

According to Juvenile Arthritis News, treating juvenile idiopathic arthritis early helps reduce symptoms, nearly "inactivating" the condition. The Canadian Alliance of Pediatric Rheumatology Investigators (CAPRI) JIA Registry found that early…

Continue Reading Early Treatment of Juvenile Idiopathic Arthritis Improves Outcomes, Inactivates Disorder
New Task Force Recommends Shared Decision-Making for Parents and Patients with Juvenile Idiopathic Arthritis
source: pixabay.com

New Task Force Recommends Shared Decision-Making for Parents and Patients with Juvenile Idiopathic Arthritis

  According to a recent article in BioMed Central, an international task force formed in 2018 created guidelines for the treatment of juvenile idiopathic arthritis (JIA). Treatment targets were identified…

Continue Reading New Task Force Recommends Shared Decision-Making for Parents and Patients with Juvenile Idiopathic Arthritis
Study: Felty’s Syndrome Presents Differently in Pediatric Patients
source: pixabay.com

Study: Felty’s Syndrome Presents Differently in Pediatric Patients

According to a study published in BMC Pediatrics, the rare disease known as Felty's syndrome is primarily known to affects adults between the ages of 50 and 70, but on very rare…

Continue Reading Study: Felty’s Syndrome Presents Differently in Pediatric Patients
ICYMI: Johnson & Johnson and the UK Government: Genomics For Disease Prevention
source: pixabay.com

ICYMI: Johnson & Johnson and the UK Government: Genomics For Disease Prevention

  Janssen R&D, a division of Johnson & Johnson (J&J), has partnered with the UK Biobank and others according to a recent news release by 3BL Media. It is noteworthy…

Continue Reading ICYMI: Johnson & Johnson and the UK Government: Genomics For Disease Prevention
Searching for the Cause of Lung Disease in Systemic Juvenile Idiopathic Arthritis
source: pixabay.com

Searching for the Cause of Lung Disease in Systemic Juvenile Idiopathic Arthritis

  According to a recent article in MedPage Today’s 2019 year-end review, the number of life-threatening lung diseases in systemic juvenile idiopathic arthritis (sJIA) patients has been increasing. sJIA is…

Continue Reading Searching for the Cause of Lung Disease in Systemic Juvenile Idiopathic Arthritis